anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrroline alkaloids; pyrrolidine alkaloids; pyrrolizidine alkaloids; indolizidine alkaloids and nortropane alkaloids.
A device is disclosed for helping a smoker to quit smoking. The device includes a shaft with a mass of nicotine chewing gum cooperative with one end. A smoker controls the timing and quantity of nicotine delivered by controlling the amount of gum chewed and the duration of chewing. In some embodiments partially depleted gum can be replaced on the shaft for later use. A cover can be included to protect the gum when not in use. The cover can be a simple paper wrapper or a rigid cover with a mechanism to attach it to the shaft. Portion indicators can divide the gum into separately chewable portions. The shaft can be a simple stick, or a hollow tube containing a supply of gum for delivery as needed. Some hollow tube embodiments expel gum from the tube using a sliding mechanism or a twisting mechanism that functions like a lipstick.
The present invention relates to a technique which stores, in response to a room reservation, a selfie and a hotel usage schedule of a hotel reserver in a safe entrance door installed on each room and verifies, when a person requesting entry appears at the hotel room, whether the person is the hotel reserver of the schedule through a face photo of the person requesting entering, obtained by a camera installed on the safe entrance door, so that the usage of the hotel room is implemented in a non-face-to-face manner, and technically confirms various dangerous situations inside and outside a hotel room during a process of opening the safe entrance door by mounting various sensors and cameras on the safe entrance door to ensure that there is no vacancy in safety management for users due to the non-face-to-face transition. Accordingly, people can conveniently and safely use hotel rooms. According to the present invention, there is an advantage in that the usage of hotels can be converted into a non-face-to-face (non-contact) manner. Switching to a non-face-to-face manner can provide advantages in terms of user convenience, management costs, and control of virus infections. In addition, if a fire breaks out inside a room or someone tries to enter the room while exhibiting violent behavior, the entrance door will not be opened. Therefore, the present invention has an advantage (anti-threat) of preventing dangerous situations for room users in advance.
BACKGROUND/AIM: Activin A is involved in the pathogenesis of human liver diseases, but its therapeutic targeting is not fully explored. Here, we tested the effect of novel, highly specific small-molecule-based activin A antagonists (NUCC-474/555) in improving liver regeneration following partial hepatectomy and halting fibrosis progression in models of chronic liver diseases (CLDs).
METHODS: Cell toxicity of antagonists was determined in rat hepatocytes and Huh-7 cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay. Hepatocytes and hepatic stellate cells (HSCs) were treated with activin A and NUCC-555 and analyzed by reverse transcription-polymerase chain reaction and immunohistochemistry. Partial hepatectomized Fisher (F)344 rats were treated with NUCC-555, and bromodeoxyuridine (BrdU) incorporation was determined at 18/24/36/120/240 h. NUCC-555 was administered into thioacetamide- or carbon tetrachloride-treated F344 rats or C57BL/6 mice, and the fibrosis progression was studied.
RESULTS: NUCC-474 showed higher cytotoxicity in cultured hepatic cells; therefore, NUCC-555 was used in subsequent studies. Activin A-stimulated overexpression of cell cycle-/senescence-related genes (e.g., p15INK4b, DEC1, Glb1) was near-completely reversed by NUCC-555 in hepatocytes. Activin A-mediated HSC activation was blocked by NUCC-555. In partial hepatectomized rats, antagonizing activin A signaling resulted in a 1.9-fold and 2.3-fold increase in BrdU+ cells at 18 and 24 h, respectively. Administration of NUCC-555 in rats and mice with progressing fibrosis significantly reduced collagen accumulation (7.9-fold), HSC activation indicated by reduced alpha smooth muscle actin+ and vimentin+ cells, and serum aminotransferase activity.
CONCLUSIONS: Our studies demonstrate that activin A antagonist NUCC-555 promotes liver regeneration and halts fibrosis progression in CLD models, suggesting that blocking activin A signaling may represent a new approach to treating people with CLD.
Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
An oral formulation comprises an outer layer, a sedative and optionally a relaxant, and an inner layer comprising a stimulant. The sedative, relaxant, and stimulant may be from a natural source. The inner layer may comprise a capsule and the outer layer may comprise a coating. The sedative may comprise melatonin, valerian root extract, hops extract, or kava extract. The relaxant may comprise chamomile extract, lavender extract, lemon balm extract, or passion flower extract. The stimulant may comprise caffeine, which may be from a green tea extract, guarana extract, coffee extract, or yerba mate extract. The sedative may comprise melatonin, the relaxant may comprise chamomile extract, and the stimulant may comprise a green tea extract. The formulation may comprise 1 mg melatonin, 1 mg chamomile extract, and 500 mg green tea extract.
Approval for the study was granted by the Clinical Research Ethics Committee and all procedures were carried out in accordance with the Helsinki Declaration. A retrospective examination was made of the anesthesia forms of patients underwent VATS May 2016 and June 2017. Due to incomplete data of 1 of these 35 patients, that case was excluded from the study. The patients were divided into two groups. 24 patients were performed SAPB and iv PCA (intravenous patient controlled analgesia) and 10 patient's pain management were provided with only PCA. No block was administered to 10 patients because of anticoagulant therapy and patient refused block application. The demographic data of the patients (age, gender, operation type, and duration) were obtained from the anesthesia forms. The postoperative pain scores of the patients, evaluated with a visual analog scale (VAS) at 1, 6, 12 and 24 hours postoperatively and the postoperative doses of analgesia used were taken from the block pain follow-up forms
Drowsiness is the usual clinical side effect. Convulsions, coma, and respiratory depression may occur with massive overdosage. No specific antidote is known. If respiratory depression occurs, mechanically assisted respiration should be initiated and oxygen should be administered. Convulsions should be treated with appropriate doses of diazepam. Phenobarbital (5 to 6 mg/kg) may be given to control convulsions in pediatric patients. 

The oral LD 50 in mice and rats is 203 mg/kg and 1320 mg/kg, respectively. The intraperitoneal LD 50 in mice is 149 mg/kg.
By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
Bone metastases are frequently one of the first signs of disseminated disease in cancer patients. Skeletal complications due to metastatic disease include (severe) bone pain, impaired mobility, spinal cord compression, pathological fractures, and hypercalcemia. Radiotherapy and surgery are the options for the specific local treatment of bone metastases. Chemotherapy, hormonotherapy and bisphosphonates are systemic weapons used in the treatment of bone metastases with or without hypercalcemia. Cancers with propensity to metastasize to bones such as breast, prostate, lung and myeloma may possess the capacity to interact with osteoclasts. Osteoclasts are specialized bone cells, which erode mineralized bone by secreting acids and lysosomal enzymes. In normal bone remodeling, osteoclastic bone resorption is coupled to and is in equilibrium with osteoblastic bone formation. The lytic bone destruction associated with malignant bone metastases develops because tumor cells synthesize and release soluble factors that stimulate osteoclasts to resorb bone. The malignant activation of osteoclasts results in a disruption of normal bone remodeling wherein the equilibrium between bone resorption and bone formation is shifted toward increased bone resorption. This relative increase in osteoclastic bone resorption results in a net loss of bone.

Zoledronic acid (Zometa®, CGP42446) is a member of a class of compounds known as bisphosphonates. Bisphosphonates are effective inhibitors of osteoclastic bone resorption. They have therapeutic efficacy in the treatments of hypercalcemia of malignancy, lytic bone disease associated with multiple myeloma, and mixed lytic and blastic bone metastases associated with breast cancer, prostate cancer and lung cancer. In the clinical setting, zoledronic acid is the most potent bisphosphonate.

Conventionally, external beam radiotherapy (RT) is a primary treatment method for the palliation of bone metastases. The aim of RT in bone metastases treatment is to eradicate malignant cells without damaging surrounding normal cells. RT is typically given to the lesion area, in order to spare as much bone marrow as possible. RT is indicated in solitary, lytic and painful bone lesions of multiple myeloma as well as bone metastases from solid tumors such as breast, prostate and lung cancer to prevent the fracture risk or to relieve the pain.

The goal of this study will be to evaluate the safety and efficacy of concomitant standard RT and standard zoledronic acid on the bone metastases of breast, prostate or lung cancer patients. We chose zoledronic acid to use in this study, as it is the most effective FDA approved aminobisphosphonate.
Patients receive Impact Advanced Recovery PO or via feeding tube BID on days 1-7 for weeks 1, 3, and 5 during chemotherapy and radiation therapy before surgery. Starting 5-7 days before surgery, patients receive Impact Advanced Recovery PO TID until surgery. Within 2 days following surgery, patients may continue to receive Impact Advanced Recovery via feeding tube at the discretion of the treating physician.
Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
PURPOSE:To obtain a coated medicinal drug effective to keep a sublimable drug stably for a long period preventing the sublimation of the sublimable drug, by coating a sublimable drug with a coating agent containing a cyclodextrin. CONSTITUTION:A coated medicinal drug can be prepared by coating a sublimable drug (e.g. menthoal, ethenzamide, cyclandelate, anthracene, etc.) with a coating agent containing a cyclodextrin. The cyclodextrin is alpha-, beta- or gamma-cyclodextrin, tri-O-methyl-cyclodextrin, etc. The amount of cyclodextrin is preferably about 3-40wt% based on the coating agent and about 3-600wt% based on the sublimable drug. When 5-methyl-2-(1-methylcyclohexyl)-4- oxazoleacetic acid is used as the sublimable drug, it can be administered orally and safely as a remedy for diabetes.
Cohorts 1-4 are SYHA1813 combined with different regimens. Cohorts 5-8 are SYHA1813 monotherapy.
Atrial fibrillation (AF) is the most common cardiac arrhythmia and can cause serious complications. Several studies have shown that neutrophils may influence AF progression. However, the key genes related to neutrophils in AF have not been fully elucidated. Here, we downloaded microarray expression data of AF, and screened differentially expressed genes. Key immune cells in AF were identified by immune cell infiltration analysis. Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) analysis were used to construct gene co-expression modules and identify hub genes. The association between key genes and neutrophils was then verified. Our results showed that 303 differentially expressed genes (DEGs) were screened in AF and sinus rhythm (SR), of which 194 were up-regulated and 109 were down-regulated. DEGs were mainly enriched in functions and pathways of neutrophil activation and biological functions of neutrophil activation-mediated immune response. Immune infiltration analysis revealed elevated levels of neutrophil infiltration in AF. WGCNA analysis revealed that the modules in dark red were associated with neutrophils. PPI analysis of these modules yielded 10 hub genes. S100A12, FCGR3B and S100A8 are 3 potential key genes related to neutrophils in AF, which are significantly positively correlated with neutrophils. These genes deserve further investigation and may be potential therapeutic targets for AF.
FIELD: biochemistry, organic chemistry, pharmacy. SUBSTANCE: product: amino acid derivatives of the general formula(I) where R- vinyl, aryl, heteroaryl, etc.; Ais L- or D-amino acid; B - group A-NRRor -Rwhere A- lipophilic amino acid containing unsubstituted phenyl or phenyl substituted with 1-3 similar or different substituents. Also, invention relates with a method of synthesis of amino acid derivatives of formula (I) mentioned above. Method involves the by-step condensation of the corresponding amino acid or partial sequences of peptide derivatives, carboxylic acids and amines by known procedures and synthesized compound is isolated as a free substance, as isomer mixture or separate isomers or as a salt, and also the pharmaceutical composition containing amino acid derivatives of formula (I) mentioned above as an active substance taken at effective amount and if necessary pharmaceutically acceptable carrier. EFFECT: improved method of synthesis.
Patients in the experimental group will undergo 10 sessions (about 2 each week) of rehabilitation treatment at the outpatient clinics of the U.O. Physical Medicine and Rehabilitation Unit of the Rizzoli Orthopedic Institute. The rehabilitation protocol consists of a series of commuting exercises and passive/active mobilization exercises of the glenohumeral joint.
In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as "Forest of Serenity", "Calm Place", "Happy Place", "Gala 360 Travel \& Relax". Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video.
OBJECTIVE: After initial treatment, up to 30% of patients with papillary thyroid cancer (PTC) have incomplete response, mainly cervical lymph node (LN) disease. Previous studies have suggested that active surveillance (AS) is a possible option for these patients. Our aim was to report the results of AS in patients with PTC and cervical LN disease.
MATERIALS AND METHODS: In this retrospective observational study, we included adult patients treated and followed for PTC, who presented with cervical LN disease and were managed with AS. Growth was defined as an increase ≥ 3mm in either diameter.
RESULTS: We included 32 patients: 27 (84.4%) women, age of 39 ± 14 years, all initially treated with total thyroidectomy, and 22 (69%) with therapeutic neck dissection. Cervical LN disease was diagnosed 1 year (0.3-12.6) after initial management, with a diameter of 9.0 mm (6.0-19.0). After a median AS of 4.3 years (0.6-14.1), 4 (12.5%) patients had LNgrowth: 2 (50%) of whom were surgically removed, 1 (25%) was effectively treated with radiotherapy, and 1 (25%) had a scheduled surgery. Tg increase was the only predictive factor of LN growth evaluated as both the delta Tg (p < 0.0366) and percentage of Tg change (p < 0.0140). None of the included patients died, had local complications due to LN growth or salvage therapy, or developed distant metastases during follow-up.
CONCLUSION: In selected patients with PTC and suspicious cervical LNs diagnosed after initial treatment, AS is a feasible and safe strategy as it allows effective identification and treatment of the minority of patients who progress.
The invention relates to a medical mask for eliminating acnes. The mask is prepared from materials of salicylic acid, alum, borneol, allantoin, cyclodextrin, polypropylene glycol, starch adhesive, Vitamin E, Vitamin B, and ethanol, and Chinese herbal medicines of sarcandra glabra (thumb.) nakai leachate and cucumber extract. Borneol, alum, sarcandra glabra (thumb.) nakai leachate and cucumber extract provide strong skin cleaning, sterilizing and inflammation eliminating effects. Cyclodextrin serves for absorbing and complexing sebum secreted from skins. Allantoin assists in promoting the growth of healthy skins, and in healing scars. Vitamin E and Vitamin B have anti-oxidant and nourishing effects. The medical mask provided by the present invention has effects of skin cleaning, sebum removing, heat clearing, detoxifying, sterilizing, and inflammation eliminating. The medical mask brings substantial effects of acne treating and acne scar healing promoting.
The framework of the primary suicide prevention intervention is psychoeducation. The intervention lasts for 90 minutes and is conducted in groups of 5 to 15 (on average 10) participants. It provides general information on suicidal behaviors, information about facts and myths about suicide, identification of risk factors and warning signs of suicidal behaviors, and information on ways to seek for help and get support for themselves and others in the canton. The intervention includes a lecture, group discussions based on case examples, and a quiz on facts and myths about suicide. It is conducted by a trained staff member with the support of a psychologist trained in suicide prevention for children and adolescents. It follows a standardized format.
The purpose of this study is to determine the tolerability and safety of the biodegradable extended release Latanoprost subconjunctival insert for primary open angle glaucoma (POAG) and ocular hypertension (OHT) patients. Intraocular pressure lowering ability of biodegradable extended release Latanoprost subconjunctival insert in POAG and OHT patients will also be evaluated.

Low dose inserts have an initial release rate of approximately 1 µg/day slowing to 0.2 µg/day after approximately 10 days; this release rate is maintained. High dose inserts have an initial release of approximately 4 µg/day, which slows to approximately 1 ug/day after 10 days. Each drop of Xalatan (the commercial form of latanoprost) contains approximately 1 µg of latanoprost. The first cohort will receive inserts that initially provide the same dose as is administered topically before their release rate slows down to a lower dose. The inserts used in this study are composed of a drug core in a (Poly Lactic Glycolic acid) PLGA polymer tube. One end of the tube is capped with an impermeable polymer (silicone) and the other end with a permeable polymer (Polyvinyl alcohol). Drug release occurs across the permeable end and is a function of internal diameter of the tube. Low dose insert and high dose insert are exactly the same except that for low dose inserts the internal diameter of the PLGA tubes is smaller. Thus different release rates (and drug loading) are obtained with the same formulation. Inserts are designed to provide steady state release for 3-6 months.
Regular physical activity improves physical and mental health and reduces the risk of heart disease, stroke, cancer, diabetes, dementia, obesity and premature death from any cause (Department of Health \& Prevention., 2004). Unfortunately the majority of adults are not active enough to reap these benefits (Chaudhury \& Roth, 2006). Specific psychological techniques can be used to overcome the known barriers to increased activity. People who are inactive can be identified in primary care through the use of standard risk tools. Similarly, standard risk tools can identify people at high risk of stroke, heart disease and diabetes, and people at risk from dementia are identified by a diagnosis of mild cognitive impairment. Combining these clinical indicators can identify people who are inactive and at highest risk who may therefore benefit most from activity interventions. These high risk patients can be offered physical activity programmes that are designed to increase longterm adherence. Aerobic dance is an activity that combines physical, social and cognitive stimulation and allows easily adjusted intensity levels to meet individual needs. Engagement in an activity program also provides opportunities to offer advice on healthy nutrition and associated meal preparation skills. Information technology can be used to increase activity participation. Video materials can be produced to guide activity participation at home, thereby increasing overall activity participation.

TRIAL DESIGN The investigators plan a longitudinal study where participants will be followed up for a total of 24 weeks. Outcome measures will be collected at three time points that separates two phases. Phase 1 consists of the group based weekly intervention plus access to online material and Phase 2 consists of only access to the online material. The time points are: baseline (Time 0), 12 weeks post intervention (Time 1) and 24 weeks post intervention (Time 2). Outcomes measured at time 1 will be used to determine the effects of Phase 1 immediately following participation, and measure at 24 weeks (Time 2) to determine the outcomes 12 weeks after the end of the group based intervention intervention and therefore the longer term effects with support from online material only. Participants will therefore serve as their own controls during Phase 2 for comparison with Phase 1. In other words the investigators will compare the results for each participant following Phase 1 with their results following Phase 2 to determine the effects of removing the group facilitation.